Get the Stockscreener App
7.99
0.88%
0.07
Novavax Inc stock is traded at $7.99, with a volume of 10.12M.
It is up +0.88% in the last 24 hours and down -9.31% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
See More
Previous Close:
$7.92
Open:
$8.05
24h Volume:
10.12M
Relative Volume:
2.47
Market Cap:
$1.28B
Revenue:
$847.25M
Net Income/Loss:
$-284.86M
P/E Ratio:
-3.4891
EPS:
-2.29
Net Cash Flow:
$-112.35M
1W Performance:
-2.44%
1M Performance:
-9.31%
6M Performance:
-38.25%
1Y Performance:
+100.75%
1-Day Range:
$7.8027
$8.54
1-Week Range:
$7.70
$8.54
52-Week Range:
$3.81
$23.86
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Compare NVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
7.99 | 1.28B | 847.25M | -284.86M | -112.35M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Moderna, Novavax rise as new bat coronavirus identified in China - MSN
Novavax to Report Q4 Earnings: Here's What You Can Expect - MSN
Novavax (NVAX) Declines More Than Market: Some Information for Investors - Yahoo Finance
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025 - Kilgore News Herald
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Novavax COVID-19 vaccine gets green light from CDC; will be available in coming weeks - The National Desk
Novavax Soars on $1.2 Billion Sanofi Vaccine Licensing Deal - MSN
Novavax, Inc. (NASDAQ:NVAX) Receives $17.83 Consensus PT from Brokerages - MarketBeat
Brokerages Set Novavax, Inc. (NASDAQ:NVAX) Price Target at $17.83 - MarketBeat
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Pending US vaccine decisions as Kennedy takes top health job - Reuters
Respiratory Syncytial Virus Therapeutics Market to Hit USD 4.64 Billion by 2032, Growing at a 14.5% CAGR – SNS Insider - GlobeNewswire Inc.
Novavax To Get $350 Mln For Unused COVID Shots From Canada - BW Healthcare World
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Novavax's CEO Stanley Erck To Retire - BW Healthcare World
Novavax (NVAX) Outperforms Broader Market: What You Need to Know - Yahoo Finance
(NVAX)Analyzing Novavax's Short Interest - Benzinga
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
- GuruFocus.com
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - MSN
Zacks Research Issues Positive Forecast for Novavax Earnings - MarketBeat
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
Zacks Research Has Positive Estimate for Novavax Q2 Earnings - MarketBeat
Novavax (NASDAQ:NVAX) Trading Down 5.7%Time to Sell? - MarketBeat
Novavax (NASDAQ:NVAX) Shares Down 5.7%Time to Sell? - MarketBeat
This Biotech Stock Plunged 20% but Wall Street Expects a 195% Recovery - MSN
COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit - MSN
(NVAX) Long Term Investment Analysis - Stock Traders Daily
New Strong Buy Stocks for January 30th - Yahoo Finance
Moderna stock rises following RFK Jr's comments - MSN
Nanopharmaceuticals Market Generated Opportunities, Future - openPR
Novavax, Inc. (NVAX) Stock: The Under-the-Radar Stock Poised for Massive Upside in 2025 - MSN
Moderna stock rises following RFK Jr's comments By Investing.com - Investing.com South Africa
Novavax (NASDAQ:NVAX) delivers shareholders strong 122% return over 1 year, surging 11% in the last week alone - Simply Wall St
Novavax falls after guidance cut on lower vaccine sales - MSN
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Novavax Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Novavax, Inc. (NASDAQ:NVAX) is Shah Capital Management's 2nd Largest Position - MarketBeat
Novavax, Inc. (NVAX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Novavax (XTER:NVV1) Short-Term Capital Lease Obligation : €9.68 Mil (As of Sep. 2024) - GuruFocus.com
Novavax (XTER:NVV1) Free Cash Flow : €-112.35 Mil (TTM As of Sep. 2024) - GuruFocus.com
Novavax (NASDAQ:NVAX) Shares Up 6.1%Here's Why - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Novavax, Inc. (NVAX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Trump Administration Halts All Communications From The Centers For Disease Control As Bird Flu Spreads - Benzinga
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novavax Inc Stock (NVAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kelly James Patrick | EVP, CFO and Treasurer |
Dec 31 '24 |
Option Exercise |
0.00 |
35,000 |
0 |
49,508 |
| Rodgers Richard J | Director |
Oct 29 '24 |
Option Exercise |
0.00 |
3,800 |
0 |
14,270 |
| King Rachel K. | Director |
Dec 13 '24 |
Sale |
9.02 |
4,150 |
37,435 |
14,770 |
| YOUNG JAMES F | Director |
Dec 31 '24 |
Sale |
8.00 |
5,400 |
43,200 |
51,760 |
| YOUNG JAMES F | Director |
Dec 24 '24 |
Sale |
8.48 |
4,600 |
39,008 |
57,160 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):